最近最经典中文mv字幕-最近韩国电影免费高清hd-最近的中文字幕大全免费-最近日韩中文字幕中文翻译歌词

您好,歡迎來到上海士研管理咨詢有限公司
產業峰會 演講局 專家智庫服務 峰會活動服務 整合營銷服務
  • 產業峰會:
    以專業團隊對產業和市場客觀詳實地調研為前提,擁有戰略性、系統性、全球性的基因,匯集了領導者關注的熱點話題與領袖代表,為您提供“一站式”的對話、分享、社交平臺!
  • 演講局:
    致力于為全球企業和機構提供主題演講家、高管大師班、董事會顧問,每項服務都提供了一種更深入、更具互動性的體驗,尤其是針對較小的精選受眾和關鍵個人。我們擁有最具影響力的商業領袖和頂級專家的資源,他們是各自領域的最杰出的代表。我們的團隊由經驗豐富的演講和活動經理組成,我們注重建立長期而深入的伙伴關系。
  • 專家智庫服務:
    中國領先的行業專家知識信息服務供應商,為需要專業洞見的商業決策者匹配具有一手經驗的行業專家,助力他們以更加明確的目標和堅定的信心做出決策。我們有60萬余名專家顧問遍布二十多個行業,而且每天還在增加!
  • 峰會活動服務:
    致力于成為全球最專業的產業峰會活動提供商,為企業和機構的產業性峰會活動提供一站式專業服務,包括調研策劃、定制邀請、營銷推廣、運營組織、項目管理、直播與數字化會議等,每項服務都由經驗豐富的專業團隊匹配長期沉淀的產業資源予以卓越執行,我們注重建立長期而深入的伙伴關系。
  • 整合營銷服務:
    致力于成為全球領先的2B營銷服務機構,聚焦產業高端活動、內容、渠道的建設與沉淀,為客戶提供一站式整合營銷解決方案,助力企業線上線下獲客與品牌筑造。我們深信專業團隊匹配產業資源帶來卓越執行,我們注重建立長期而深入的伙伴關系。
會議贊助商
7
2026 - 01 - 27
點擊次數:
迪普深合以前沿的諾貝爾獎“點擊化學(Click Chemistry)”技術為核心,是全球目前唯一的該技術的商業化實體。公司通過自主開發的“模塊化的點擊化合物庫”構建方法,突破傳統化學合成的局限,實現精準、快速的超高通量合成,切實實現以用戶為中心,構建專屬分子庫;并可直接用于活性篩選。公司正全力構建全球領先的點擊化學分子砌塊庫,隨著這一點擊化合物庫的逐步建設與一個個運用點擊化學技術的實例落地,公司正逐步成長為藥物研發、化妝品、石化、農藥及材料科學等領域的探索者與賦能者,為這些行業的合作伙伴提供從源頭分子的創新與結構優化,到關鍵技術的全方位支持;最終有望提高社會整體的科研、化工生產的效率。Core Technology and InnovationDeepSyn Pharmaceutical R&D(Shanghai)Co.,Ltd.(DeepSyn) centers its operations on the cutting-edge, Nobel Prize-winning "Click Chemistry" technology and is currently the world’s only commercial entity dedicated to this technology. Through its proprietary "modular click compound library" construction methodology, the company breaks through the constraints of traditional chemical synthesis. It achieves precise, rapid, and ultra-high-throughput synthesis, focusing on a user-centric approach to build exclusive molecular libraries that can be directly applied to activity screening.Industry Empowerment and VisionThe company is fully committed to establishing a world-leading library of click chemistry molecular building blocks. As this library is progressively developed and practical applications of click chemistry technology are realized, DeepSyn is evolving into an explorer and enabler in several key sectors:· Target Industries: These include pharmaceutical R&D, cosmetics, petrochemicals, pesticides, and materials science7.· Comprehensive Support: The company provides partners with full-spectrum assistance, from the innovation and structural optimization of source molecules to essential technical support.· Social Impact: These efforts are ultimately expected to enhance the overall efficiency of scientific research and industrial chemical production for society.
8
2026 - 01 - 27
點擊次數:
成都先導藥物開發股份有限公司(上海證券交易所股票代碼:688222.SH,股票名稱:成都先導)致力于打造國際領先的創新型生物醫藥企業,總部位于中國成都,在英國劍橋、美國休斯頓設有子公司。公司聚焦小分子及核酸新藥的發現與優化,著力打造了國際領先的DNA編碼化合物庫技術(DEL)平臺,并拓展了基于分子片段和三維結構信息的藥物設計技術(FBDD/SBDD)、基于寡核苷酸的藥物研發技術(OBT)和靶向蛋白降解技術(TPD)的核心技術平臺;同時,公司正在建設DEL+AI+自動化DMTA(設計-合成-測試-分析)分子優化能力平臺,以期加速臨床前候選藥物發現及優化過程。通過新藥研發服務、不同階段在研項目轉讓以及遠期的藥物上市等多元化的商業模式,成都先導與全球數百家制藥公司、生物技術公司、化學公司、基金會以及科研機構建立了合作。目前,公司有多個內部新藥項目處于臨床及臨床前不同階段。About HitGen Inc.HitGen Inc. (SSE: 688222.SH), is a drug discovery research company headquartered in Chengdu, China, with subsidiaries in Cambridge, UK and Houston, USA. HitGen has established leading technology platforms to enable the discovery and optimization of small molecules and nucleic acid-based drugs. Our key technology platforms include world-leading DNA-encoded library technology (DEL), fragment-based drug discovery and structure-based drug design technologies (FBDD/SBDD), as well as the emerging technology platforms for oligonucleotide-based therapeutics (OBT), and targeted protein degradation technology (TPD). Meanwhile, we are developing a DEL+AI+ Automated DMTA (Design-Make-Test-Analyze) molecular optimization platform to accelerate the discovery and optimization process of preclinical candidate compounds. Through our diverse and flexible business models, we have built up collaboration partnerships with several hundred biopharmaceutical research organizations worldwide. HitGen has multiple programmes from early discovery to clinical trial stage.官網鏈接:https://www.hitgen.com/cn
9
2026 - 01 - 27
點擊次數:
蛋白質是生物功能的主要載體,如果能像基因測序一樣直接破譯蛋白的一級結構,對了解生命活動的分子機制具有重大意義。Rapid Novor一直致力于無需基因序列的蛋白從頭測序技術,是全球首個提供單克隆抗體自動化測序服務的公司。目前Rapd Novor擁有全球最大的蛋白測序質譜平臺,是蛋白從頭測序技術的領跑者。RapdNovor的蛋白從頭測序技術已被應用于多發性骨髓瘤MRD監測,可以直接對人血清高濃度單克隆免疫球蛋白進行測序,并獲得美國CLIA臨床認證。上海快序生物科技有限公司是加拿大Rapid Novor 的中國公司。快序生物在中國提供的服務包括:抗體測序,抗體發現,腫瘤新抗原鑒定服務等。Rapid Novor Shanghai Kuaixu Biotechnologies Co., Ltd. )has the world's leading de novo protein sequencing technologyand is commited to the applicationof this technolosy in the medical field. De novo sequencing is a technique that does not rely on existing DNA or protein database information and directlydetermines the amino acid sequence of proteins. Based on this technology. Rapid Novor(Kuaikxu) has established a new platform for antibody discovery andneoantigen identification. The antibody discovery platform can directly sequence antibody proteins in the serum ofimmunized animals or humans to obtainnatural antibody sequences, thereby significantly shortening the cycle of antibody drug development. However, drect sequencing of the MHC-bound peptidesegmentto obtain the actualpresented neoantigen sequence completely changes the previous discovery mode of neoantigens, which was mainly predicted bythe gene sequencing and algorthm. Rapid Novor (Kuaixu) has always been commited to developing the next generation of protein sequencing technology todecode the immune system and benefit human health.官網鏈接:https://www.kuaixu.com/
微信公眾號
領導者網絡APP
友情鏈接
Copyright ?2005 - 2017上海士研管理咨詢有限公司
犀牛云提供企業云服務